Our Science

At the heart of our research is M10, a small peptide that modulates the TGF-β1 pathway—a key driver of fibrosis—by inhibiting downstream inflammatory and fibrotic processes.

Our groundbreaking research, first published in the April 2016 issue of Translational Research, demonstrated the potential of our proprietary peptide M10 as a preventive treatment against fibrotic damage in patients with systemic sclerosis, particularly in those who develop interstitial lung diseases (ILD), its deadliest complication.

In September 2021, we were awarded an STTR Phase I grant, which successfully determined the efficacious dose of M10 in two preclinical animal models of systemic sclerosis-associated interstitial lung disease (SSc-ILD).  As the company advances, it aims to partner with industry leaders to bring this promising therapeutic candidate closer to clinical trials and ultimately, patient care.